Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.: Anti-HER3 antibodies in cancer therapy

Yassamine Lazrek 1, 2 Olivier Dubreuil 2 Véronique Garambois 1 Nadège Gaborit 1 Christel Larbouret 1 Christophe Le Clorennec 1 Gaelle Thomas 1 Wilhem Leconet 1 Marta Jarlier 1 Martine Pugnière 1 Nadia Vié 1 Bruno Robert 1 Céline Monnet 2 Khalil Bouayadi 2 Hakim Kharrat 2 Philippe Mondon 2 André Pèlegrin 1 Thierry Chardès 1, *
* Auteur correspondant
1 IRCM - U896 Inserm - UM1 - Institut de recherche en cancérologie de Montpellier
2 Millegen SA
Abstract : Blockade of the human epidermal growth factor receptor 3 (HER3) and of the downstream phosphatidylinositide 3-kinase (PI3K)/AKT pathway is a prerequisite for overcoming drug resistance and to develop novel treatments for cancers that are not eligible for the currently approved targeted therapies. To this end, we generated specific antibodies (Abs) against domain 1 (D1) and domain 3 (D3) of HER3 that recognize epitopes that do not overlap with the neuregulin-binding site. The fully human H4B-121 Ab and the mouse monoclonal Abs 16D3-C1 and 9F7-F11 inhibited tumor growth in nude mice xenografted with epidermoid, pancreatic, or triple-negative breast cancer cells. The combination of one anti-HER3 Ab and trastuzumab improved tumor growth inhibition in mice xenografted with HER2(low) cancer cell lines, for which trastuzumab alone shows no or moderate efficiency. Ab-induced disruption of tumor growth was associated with G1 cell cycle arrest, proliferation inhibition, and apoptosis of cancer cells. Anti-HER3 Abs blocked HER2/HER3 heterodimerization and HER3 phosphorylation at the cell membrane, leading to inhibition of phosphorylation of the downstream AKT targets murine double minute 2, X-linked inhibitor of apoptosis, and forkhead box O1. This study demonstrates that anti-HER3 D1 and D3 Abs could represent a new option for immunotherapy of pancreatic and triple-negative breast cancers.
Keywords : HER3 cancer antibody signaling treatment
Type de document :
Article dans une revue
Neoplasia : An International Journal for Oncology Research, Elsevier, 2013, 15 (3), pp.335-47
Liste complète des métadonnées

Littérature citée [46 références]  Voir  Masquer  Télécharger
http://www.hal.inserm.fr/inserm-00815985
Contributeur : Yves Le Ster <>
Soumis le : dimanche 1 septembre 2013 - 07:00:15
Dernière modification le : mercredi 3 octobre 2018 - 16:02:21
Document(s) archivé(s) le : lundi 3 avril 2017 - 07:54:12

Fichier

Neoplasia_Lazrek_Y-Chardes_T-_...
Fichiers produits par l'(les) auteur(s)

Identifiants

  • HAL Id : inserm-00815985, version 1
  • PUBMED : 23479511

Collections

FNCLCC | VALDAURELLE | BS | UNIV-MONTPELLIER

Citation

Yassamine Lazrek, Olivier Dubreuil, Véronique Garambois, Nadège Gaborit, Christel Larbouret, et al.. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.: Anti-HER3 antibodies in cancer therapy. Neoplasia : An International Journal for Oncology Research, Elsevier, 2013, 15 (3), pp.335-47. 〈inserm-00815985〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

1127

Téléchargements de fichiers

534

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD